Thrombosis profilaxis terhesseg alatt kis molekulatomegu heparinnal

Translated title of the contribution: Thrombosis prophylaxis in pregnancy using low molecular weight heparins (LMWH)

A. Pajor, L. Lukacsi, A. Sebestyen, Z. Fontanyi, L. Nemes, F. Paulin

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Efficacy and adverse effects of an LMWH (enoxaparin) administered for thrombosis prophylaxis in 38 pregnancies of 35 women with high risk for venous thrombosis were studied. Enoxaparin was used in 20 women with missed abortion prior to emptying the uterus, in one woman before cerclage and in 6 women before caesarean section. In addition it was used for prophylaxis in 11 pregnancies in 8 thrombophilic patients. No increased blood loss was observed during abortion, delivery and caesarean section. No adverse effects were noted. No postoperative thrombosis occured. Out of the 11 pregnancies with thrombophilia one woman has had thrombosis. It occured at the 26th gestational week while using 20 mg of enoxaparin daily. Fetal outcome in pregnancies of thrombophilic patients improved during treatment. Placental infarcts in patients with antiphospholipid antibodies were however, visible even after using 20, 40 and 60 mg of enoxaparin daily. Data suggest that a daily dose of 20-40 mg of enoxaparin is effective and safe for preventing postoperative thrombosis, however, a higher dose seems to be required for prevention of venous and placental thromboses in women with antiphospholipid antibodies.

Original languageHungarian
Pages (from-to)337-342
Number of pages6
JournalMagyar Noorvosok Lapja
Volume62
Issue number5
Publication statusPublished - 1999

Fingerprint

Low Molecular Weight Heparin
Enoxaparin
Thrombosis
Pregnancy
Antiphospholipid Antibodies
Venous Thrombosis
Cesarean Section
Missed Abortion
Thrombophilia
Pregnancy Outcome
Uterus

ASJC Scopus subject areas

  • Obstetrics and Gynaecology

Cite this

Pajor, A., Lukacsi, L., Sebestyen, A., Fontanyi, Z., Nemes, L., & Paulin, F. (1999). Thrombosis profilaxis terhesseg alatt kis molekulatomegu heparinnal. Magyar Noorvosok Lapja, 62(5), 337-342.

Thrombosis profilaxis terhesseg alatt kis molekulatomegu heparinnal. / Pajor, A.; Lukacsi, L.; Sebestyen, A.; Fontanyi, Z.; Nemes, L.; Paulin, F.

In: Magyar Noorvosok Lapja, Vol. 62, No. 5, 1999, p. 337-342.

Research output: Contribution to journalArticle

Pajor, A, Lukacsi, L, Sebestyen, A, Fontanyi, Z, Nemes, L & Paulin, F 1999, 'Thrombosis profilaxis terhesseg alatt kis molekulatomegu heparinnal', Magyar Noorvosok Lapja, vol. 62, no. 5, pp. 337-342.
Pajor A, Lukacsi L, Sebestyen A, Fontanyi Z, Nemes L, Paulin F. Thrombosis profilaxis terhesseg alatt kis molekulatomegu heparinnal. Magyar Noorvosok Lapja. 1999;62(5):337-342.
Pajor, A. ; Lukacsi, L. ; Sebestyen, A. ; Fontanyi, Z. ; Nemes, L. ; Paulin, F. / Thrombosis profilaxis terhesseg alatt kis molekulatomegu heparinnal. In: Magyar Noorvosok Lapja. 1999 ; Vol. 62, No. 5. pp. 337-342.
@article{86ee6de50ff14848a3a7b49750c389e7,
title = "Thrombosis profilaxis terhesseg alatt kis molekulatomegu heparinnal",
abstract = "Efficacy and adverse effects of an LMWH (enoxaparin) administered for thrombosis prophylaxis in 38 pregnancies of 35 women with high risk for venous thrombosis were studied. Enoxaparin was used in 20 women with missed abortion prior to emptying the uterus, in one woman before cerclage and in 6 women before caesarean section. In addition it was used for prophylaxis in 11 pregnancies in 8 thrombophilic patients. No increased blood loss was observed during abortion, delivery and caesarean section. No adverse effects were noted. No postoperative thrombosis occured. Out of the 11 pregnancies with thrombophilia one woman has had thrombosis. It occured at the 26th gestational week while using 20 mg of enoxaparin daily. Fetal outcome in pregnancies of thrombophilic patients improved during treatment. Placental infarcts in patients with antiphospholipid antibodies were however, visible even after using 20, 40 and 60 mg of enoxaparin daily. Data suggest that a daily dose of 20-40 mg of enoxaparin is effective and safe for preventing postoperative thrombosis, however, a higher dose seems to be required for prevention of venous and placental thromboses in women with antiphospholipid antibodies.",
keywords = "Low molecular weight heparin, Pregnancy, Thrombosis",
author = "A. Pajor and L. Lukacsi and A. Sebestyen and Z. Fontanyi and L. Nemes and F. Paulin",
year = "1999",
language = "Hungarian",
volume = "62",
pages = "337--342",
journal = "Magyar Noorvosok Lapja",
issn = "0025-021X",
publisher = "Magyar Noovos Tarsasag",
number = "5",

}

TY - JOUR

T1 - Thrombosis profilaxis terhesseg alatt kis molekulatomegu heparinnal

AU - Pajor, A.

AU - Lukacsi, L.

AU - Sebestyen, A.

AU - Fontanyi, Z.

AU - Nemes, L.

AU - Paulin, F.

PY - 1999

Y1 - 1999

N2 - Efficacy and adverse effects of an LMWH (enoxaparin) administered for thrombosis prophylaxis in 38 pregnancies of 35 women with high risk for venous thrombosis were studied. Enoxaparin was used in 20 women with missed abortion prior to emptying the uterus, in one woman before cerclage and in 6 women before caesarean section. In addition it was used for prophylaxis in 11 pregnancies in 8 thrombophilic patients. No increased blood loss was observed during abortion, delivery and caesarean section. No adverse effects were noted. No postoperative thrombosis occured. Out of the 11 pregnancies with thrombophilia one woman has had thrombosis. It occured at the 26th gestational week while using 20 mg of enoxaparin daily. Fetal outcome in pregnancies of thrombophilic patients improved during treatment. Placental infarcts in patients with antiphospholipid antibodies were however, visible even after using 20, 40 and 60 mg of enoxaparin daily. Data suggest that a daily dose of 20-40 mg of enoxaparin is effective and safe for preventing postoperative thrombosis, however, a higher dose seems to be required for prevention of venous and placental thromboses in women with antiphospholipid antibodies.

AB - Efficacy and adverse effects of an LMWH (enoxaparin) administered for thrombosis prophylaxis in 38 pregnancies of 35 women with high risk for venous thrombosis were studied. Enoxaparin was used in 20 women with missed abortion prior to emptying the uterus, in one woman before cerclage and in 6 women before caesarean section. In addition it was used for prophylaxis in 11 pregnancies in 8 thrombophilic patients. No increased blood loss was observed during abortion, delivery and caesarean section. No adverse effects were noted. No postoperative thrombosis occured. Out of the 11 pregnancies with thrombophilia one woman has had thrombosis. It occured at the 26th gestational week while using 20 mg of enoxaparin daily. Fetal outcome in pregnancies of thrombophilic patients improved during treatment. Placental infarcts in patients with antiphospholipid antibodies were however, visible even after using 20, 40 and 60 mg of enoxaparin daily. Data suggest that a daily dose of 20-40 mg of enoxaparin is effective and safe for preventing postoperative thrombosis, however, a higher dose seems to be required for prevention of venous and placental thromboses in women with antiphospholipid antibodies.

KW - Low molecular weight heparin

KW - Pregnancy

KW - Thrombosis

UR - http://www.scopus.com/inward/record.url?scp=0032833542&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0032833542&partnerID=8YFLogxK

M3 - Article

VL - 62

SP - 337

EP - 342

JO - Magyar Noorvosok Lapja

JF - Magyar Noorvosok Lapja

SN - 0025-021X

IS - 5

ER -